Is obesity associated with the prognosis of papillary thyroid carcinoma?

I would like to take this opportunity to respond to some of the questions raised by Sun and Liu (1) in the subsequent comments of my paper “The clinical importance of overweight or obesity on tumor recurrence in papillary thyroid carcinoma” (2).

First of all, I strongly agree with the authors’ view of the association overweight or obesity and poor prognosis of papillary thyroid carcinoma. They pointed out two aspects: (I) un-differentiation of overweight state and obesity; (II) and unknown duration of overweight or obese state. Both may cover up the significance of obesity.

First, I discuss un-differentiation of overweight state and obesity.

Diagnosis of obesity and treatment decisions are based on a body mass index (BMI) greater than or equal to 30 kg/m² in obesity treatment guidelines (3-6).

Many extensive population studies have showed a J-shaped relationship between BMI and mortality or morbidity (7,8). A BMI greater than or equal to 30 kg/m² (which defines obesity in guidelines) is associated with increased mortality or morbidity (7,8).

World Health Organization (WHO) describes “for adults, WHO defines overweight and obesity as follows: overweight is a BMI greater than or equal to 25; and obesity is a BMI greater than or equal to 30”. And “BMI provides the most useful population-level measure of overweight and obesity as it is the same for both sexes and for all ages of adults. However, it should be considered a rough guide because it may not correspond to the same degree of fatness in different individuals” (9).

Therefore, the WHO Asia-Pacific region (10) and the Korean Society of Obesity (11) defined obesity as a BMI greater than or equal to 25 kg/m², based on evidence for a significant increase in obesity-related diseases. In conclusion, a BMI greater than or equal to 25 meets the definition of obesity in Korea. And to avoid confusion, I have marked a BMI greater than or equal to as overweight or obese.

In the meta-analysis written by Renehan et al. (12), mentioned by the authors, only 1 out of 5 thyroid papers was Asia-pacific. It showed a 5 kg/m² increased BMI was strongly associated with the incidence of thyroid carcinoma (1.33, P=0.02) (12), not the prognosis of thyroid carcinoma.

And my study has few patients with a BMI greater than or equal to 30 kg/m², so I did not draw any meaningful analysis results based on a BMI greater than or equal to 30 kg/m². However, now that the number of obese people is increasing more than before, I think the prognosis of papillary thyroid carcinoma in people with a BMI greater than or equal to 30 kg/m² will be different.

Second, I discuss unknown duration of overweight or obese state. Both may cover up the significance of obesity.

In fact, I really want to know duration of overweight or obese state of patients with papillary thyroid carcinoma. However, in this study, all patients visit the doctor once every 6 months or a year. Unless they had a metabolic disease, their weight was not measured frequently. Of the 403 patients, only 85 had additional weight records over an average 6.8 years follow-up period (median: 6.5 years). Eighty-five patients had a change in BMI, a mean of 0.35 kg/m², and a median of 0.45 (range, −10.67 to +5.62) kg/m², which is a slight change.

A prospective cohort study using US National Health and Nutrition Examination Survey including 36,051 people aged 40 years or over showed stable obesity across adulthood, weight gain from young to middle adulthood, and weight loss from middle to late adulthood were associated with increased risks of mortality (13). Therefore, when looking at weight changes, it is thought that age is also essential. It would not be possible to predict that weight changes in a 25-year-old and an 80-year-old patient would have the same prognosis.

From my limited experience, I agree with the significance of obesity in the prognosis of papillary thyroid carcinoma. I hope that a future prospective study to investigate the relationship between obesity and thyroid cancer will become.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Gland Surgery. The article did not undergo external peer review.

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-2022-05/coif). The author has no conflicts of interest to declare.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Sun Y, Liu S. Metastasis of papillary thyroid cancer: does body mass index (BMI) is the key factor? Gland Surg 2022;11:1439-40.
2. Kim JM. The clinical importance of overweight or obesity on tumor recurrence in papillary thyroid carcinoma. Gland Surg 2022;11:35-41. [Crossref] [PubMed]
3. Brauer P, Gorber SC, Shaw E, et al. Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. CMAJ 2015;187:184-95. [Crossref] [PubMed]
4. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22:1-203. [Crossref] [PubMed]
5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63:2985-3023. [Crossref] [PubMed]
6. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts 2015;8:402-24. [Crossref] [PubMed]
7. Expert Consultation WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63. [Crossref] [PubMed]
8. Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-86. [Crossref] [PubMed]
9. WHO. Obesity and overweight 2021. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
10. World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia, 2000.
11. Seo MH, Kim YH, Han K, et al. Prevalence of Obesity and Incidence of Obesity-Related Comorbidities in Koreans Based on National Health Insurance Service Health Checkup Data 2006-2015. J Obes Metab Syndr 2018;27:46-52. [Crossref] [PubMed]
12. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78. [Crossref] [PubMed]
13. Chen C, Ye Y, Zhang Y, et al. Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study. BMJ 2019;367:l5584. [Crossref] [PubMed]